Purdue University’s Student-Managed Venture Fund is betting its bank on West Lafayette-based biotech startup Kylin Therapeutics
This month, MBA students in the Krannert Graduate School of Management invested $100,000 in Kylin, which represents 77 percent
of their fund’s total assets. Kylin, in the Purdue Research Park, is in the preclinical stage of commercializing a technology
to target and "turn off" diseasecausing genes.
Including the student’s investment, Kylin last month raised $2 million in a venture capital round led by West Lafayette-based
In-vivo Ventures and Durham, N.C.-based Golden Pine Ventures. The company plans to use the money to advance its cancer therapy
to the marketplace.